New research has concluded that screening for a genetic condition in younger people who are diagnosed with bowel cancer would be cost-effective for the NHS.
Researchers at the University of Exeter Medical School were funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme to assess the effectiveness and cost-effectiveness of screening for Lynch Syndrome. Their findings, published in Health Technology Assessment, indicate that screening the 1,700 people under the age of 50 who are newly diagnosed with bowel cancer in England each year would identify two thirds of these whose cancer was caused by Lynch Syndrome. From this group, the findings suggest that 40 further cases of cancer could be avoided in them and their relatives.
AdvertisementLynch Syndrome is a condition caused by mutations in the genes responsible for proof-reading DNA. It increases the risk of developing cancer, particularly bowel cancer and cancers of the womb and ovaries. It is responsible for around one in 12 cases of bowel cancer in people aged under 50. Around a third of people with the disease would develop bowel cancer by the time they are 70 if no action is taken. If Lynch Syndrome is identified as the cause of bowel cancer, patients can be offered risk-reducing measures such as more intensive post-operative colonoscopy surveillance to spot recurrences and new cancers early. As close relatives have a 50% chance of having the condition, this testing will help identify them and ensure that they also receive appropriate care
Dr Tristan Snowsill, of the University of Exeter Medical School, said: "This is the first evidence that systematic testing for Lynch syndrome could be cost-effective in the NHS. There are health professionals in the NHS who think cost-effectiveness is the hurdle that needs to be cleared before systematic testing can be implemented; policymakers now have that evidence before them to decide if this is right for the NHS, a decision which will not be solely based on cost-effectiveness."
The team systematically reviewed all the evidence surrounding Lynch Syndrome and bowel cancer, identifying and assessing 42 studies in total, before constructing a computer model of screening strategies for Lynch Syndrome. It found that all screening strategies helped improve health outcomes at a cost generally acceptable to the NHS. The most cost-effective method of identifying Lynch Syndrome involved running tests on the tumour before offering counselling and genetic testing.
In a separate analysis, which has not yet been published or peer-reviewed, the team used the same model to estimate that 28 cancer related deaths (24 from bowel cancer and four from womb cancer) could be prevented each year if Lynch Syndrome screening for people with bowel cancer was introduced.
Dr Ian Frayling, of Cardiff University's Institute of Medical Genetics, was clinical advisor on the research. He said: "This is a very significant piece of work which is much to be welcomed. It justifies the National Health Services in the UK implementing such testing, which is already carried out in other European countries. Those with Lynch Syndrome will now be found and given the care that they warrant, saving time, lives, money and resources. And colleagues around the world are eager to use the model developed by the University of Exeter Medical School, so the benefits extend far beyond the UK."
Deborah Alsina, Chief Executive of Bowel Cancer UK, commented: "We welcome these research findings which demonstrate that lives can be saved through earlier identification of those who are at higher risk of bowel cancer because of genetic conditions like Lynch syndrome. It's critical that more lives are saved by ensuring people gain access to the screening surveillance they need, so that bowel cancer can be ruled out first, not last, in younger patients."
"While bowel cancer is thankfully relatively rare in people under 50, there are still 550 people in this age group who lose their lives to bowel cancer each year and that must change."
P No Improvement Seen With High-Dose Vitamin D for ICU Patients Who are Vitamin D Deficient 'Stealth' Nanoparticles Could Improve Cancer Vaccines: Study M
You May Also Like